Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Objective:Between 2012 and 2017, the U.S. Food and Drug Administration (FDA) approved 10 antidiabetic indicated therapies. Due to the limited literature on voluntarily reported safety outcomes for recently approved antidiabetic drugs, this study investigated adverse drug reactions (ADRs) reported in the FDA Adverse Event Reporting System (FAERS).Research Design and Methods:A disproportionality analysis of spontaneously reported ADRs was conducted. FAERS reports from January 1, 2012 to March 31, 2022 were compiled, allowing a 5-year buffer following drug approval in 2017. Reporting odds ratios were calculated for the top 10 ADRs, comparing new diabetic agents to the other approved drugs in their therapeutic class.Results:127,525 reports were identified for newly approved antidiabetic medications listed as the primary suspect (PS). For sodium-glucose co-transporter-2 (SGLT-2) inhibitors, the odds of blood glucose increased, nausea, and dizziness being reported was greater for empagliflozin. Dapagliflozin was associated with greater reports of weight decreased. Canagliflozin was found to have a disproportionally higher number of reports for diabetic ketoacidosis, toe amputation, acute kidney injury, fungal infections, and osteomyelitis. Assessing glucagon-like peptide-1 (GLP-1) receptor agonists, dulaglutide and semaglutide were associated with greater reports of gastrointestinal adverse drug reactions. Exenatide was disproportionally associated with injection site reactions and pancreatic carcinoma reports.Conclusion:Pharmacovigilance studies utilizing a large publicly available dataset allow an essential opportunity to evaluate the safety profile of antidiabetic drugs utilized in clinical practice. Additional research is needed to evaluate these reported safety concerns for recently approved antidiabetic medications to determine causality.Plain language summaryAdverse drug reactions reported for antidiabetic medicationsIntroduction: This study investigated the trends in voluntary reporting of adverse drug reactions for recently approved antidiabetic medications.Methods: Data from the FDA Adverse Events Reporting System were evaluated. The top 10 adverse drug reactions were compared between antidiabetic medications in the same therapeutic class.Results: We identified 127,525 adverse drug reaction reports for the newer approved antidiabetic medications. For SGLT-2 inhibitors, empagliflozin was associated with greater reports of blood glucose increase, nausea, and dizziness; weight decreased was reported more often for dapagliflozin; and diabetic ketoacidosis, toe amputation, acute kidney injury, fungal infections, and osteomyelitis were reported more commonly for canagliflozin. Assessing GLP-1 receptor agonists, the odds of gastrointestinal adverse drug reactions being reported was greater for dulaglutide and semaglutide. Exenatide was disproportionally associated with injection site reactions and pancreatic carcinoma reports.Conclusion: Medication safety studies using a large publicly available dataset allows an essential opportunity to evaluate the safety profile of antidiabetic drugs in the real-world setting. Additional research is needed to determine if the reported safety concerns for recently approved antidiabetic medications to determine causality.

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement

De-escalation treatment with pasireotide for acromegaly: a long-term experience

Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study

Pasireotide in the Personalized Treatment of Acromegaly

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

Combined Therapy of Somatostatin Analogues with Pegvisomant for the Treatment of Acromegaly: a Meta-Analysis of Prospective Studies

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial